8 Brain And Heart Health Rules For A Longer Life
In 2023, dementia and Alzheimer's disease were listed as the leading cause of death in England and Wales.
The second most common cause of death was heart disease, which affected 10% of all those who died in the period.
Recent data shared in the 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association has underscored years of research suggesting brain and heart health are linked.
Their stats show that a 160% increase in dementia worldwide over the past 30 years follows the trend of heart disease, which is up 111% globally in the same time period.
In a press release, the American Heart Association's former president and current chief clinical science officer, neurologist Dr Mitchell S. V. Elkind, said: 'We now know that many of the same health risk factors that cause heart disease and stroke also contribute to a decline in overall brain health.'
Dr Elkind shared that the risk of these conditions can be lowered by following eight rules, however.
Dr Elkind noted that the brain and heart connection is helpful in some ways, as helping one helps another.
'Using many of the same tools and information that have helped us successfully address cardiovascular risk factors and reduce the burden of heart disease over the past several decades, we should be able to do the same for brain disorders and promote brain health,' he said.
The expert recommended following the American Heart Association's Life Essential 8 rules for both brain and heart benefits.
These are:
Staying active
Giving up smoking, if you're a smoker
Getting enough sleep
Staying at a healthy weight
Controlling your cholesterol
Managing your blood sugar
Managing your blood pressure.
Last year, the medical journal The Lancet wrote that almost 45% of dementia cases could be preventable with some lifestyle changes.
A lot of these overlapped with the heart health company's advice; stopping smoking, exercising, managing cholesterol, sticking to a healthy weight, and managing your blood pressure all made their list.
'Just like with heart disease and stroke, most brain disease is preventable,' Dr Elkind said.
'It's critical that as a society and as individuals we understand and make the changes needed to improve health outcomes from brain disease and, more importantly, prevent them to begin with.'
I'm A Cardiologist, These 6 Easily Overlooked Symptoms Could Signal Heart Disease
How These Body Parts Age May Reveal Dementia Risk 'Decades' Before Diagnosis
Dementia Risk Doubles For Women After 65 –These Are The Early Signs You Shouldn't Ignore
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Analysis of the European Hospitals Market 2025-2030: Investment Opportunities for Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Sweden, Belgium, and Ireland
The market is poised for growth, driven by aging demographics, technological advances, and a shift to value-based care. Key opportunities lie in digital health, infrastructure upgrades, and workforce development. Addressing workforce shortages and integrating value-based models will be crucial for sustainability. European Hospital Market Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Europe Hospital Market, By Country, Competition, Forecast and Opportunities, 2020-2030F" has been added to offering. The Europe Hospital Market was valued at USD 0.85 Trillion in 2024, and is expected to reach USD 1.09 Trillion by 2030, rising at a CAGR of 4.35%. This mature and advanced market is anchored by strong public healthcare systems, cutting-edge infrastructure, and a widespread commitment to universal care access. The sector's growth is being fueled by shifting demographics, especially aging populations, along with rapid technological progress and evolving patient expectations. To maintain performance and meet rising demand, hospitals are undergoing digital transformation, expanding service capacity, and focusing on operational modernization. Investments in digital health, workforce development, and facility upgrades are becoming critical. Meanwhile, the shift toward integrated, value-based care models is redefining hospital operations and emphasizing efficiency, outcome measurement, and long-term sustainability, ensuring hospitals remain central to Europe's healthcare landscape. Key Market Driver Aging Population and Chronic Disease Burden Europe's aging population and the resulting increase in chronic diseases are major factors propelling the hospital market. By 2030, the number of Europeans living with Alzheimer's and related dementias is expected to rise to 14 million, escalating the healthcare system's financial and operational demands. The projected economic impact of Alzheimer's care is set to exceed USD 721.37 billion by 2050. As per Eurostat, individuals aged 65 and older made up 21.1% of the EU's population in 2022, and this is forecasted to rise to 32.5% by 2100. Older populations are more prone to conditions such as cardiovascular disease, diabetes, osteoporosis, neurodegenerative disorders, and cancer, all of which increase hospital care needs. Consequently, hospitals are expanding geriatric and chronic care services, modernizing infrastructure, and adapting clinical operations to manage growing patient loads. Key Market Challenge Workforce Shortages and Talent Retention The shortage of skilled medical professionals - including nurses, general practitioners, and specialists - poses a significant challenge for hospitals across Europe. Contributing factors include an aging healthcare workforce, burnout, and early retirements, particularly in under-resourced public systems. Staffing shortages reduce care quality, extend wait times, and hinder hospitals' ability to scale operations or adopt innovative models. The increased use of temporary staffing and overtime also inflates labor costs. Addressing this challenge requires strategic investment in training programs, international recruitment, and adoption of automation technologies such as AI-driven diagnostics and robotic procedures to ease clinical burdens and improve workforce efficiency. Key Market Trend Integration of Value-Based Healthcare Models European hospitals are transitioning from fee-for-service to value-based healthcare (VBHC) models, which emphasize care quality, patient outcomes, and cost-effectiveness. Government mandates and payer incentives are accelerating this shift to improve healthcare delivery and financial sustainability. Hospitals are redesigning care pathways around bundled, patient-centered services with a focus on chronic disease management, preventative care, and post-discharge support. The implementation of performance-based KPIs is reshaping reimbursement models, promoting efficiency, and reducing readmissions. Advanced analytics and predictive tools are increasingly used to track outcomes, manage resources, and demonstrate value - ultimately strengthening hospitals' competitiveness and long-term viability in the evolving European health ecosystem. Key Market Players Profiled: HCA Healthcare UK Fresenius SE & Co. KGaA Spire Healthcare Group plc Orpea Group Asklepios Klinik Barmbek Sana Kliniken AG San Donato Group (Gruppo San Donato) Report Scope In this report, the Europe Hospital Market has been segmented into the following categories: Europe Hospital Market, By Product: Public Private Europe Hospital Market, By Type: General Specialty Multi-Speciality Europe Hospital Market, By Type of Services: In-Patient Services Out-Patient Services Europe Hospital Market, By Bed Capacity: Up to 100 beds 100-500 beds Above 500 beds Europe Hospital Market, By Country: Germany France United Kingdom Italy Spain Netherlands Switzerland Sweden Belgium Ireland Key Attributes Report Attribute Details No. of Pages 125 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $0.85 Trillion Forecasted Market Value (USD) by 2030 $1.09 Trillion Compound Annual Growth Rate 4.3% Regions Covered Europe For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment European Hospital Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
‘Transformative': the UK lab working on a way to halt genetic type of dementia
Behind the gleaming glass facade of an office block in east London's Docklands, Dr Martina Esposito Soccoio is pipetting ribonucleic acid into test tubes. Here, not far from Canary Wharf's multinational banks, a British university spinout is working on a breakthrough treatment for a form of dementia that affects millions of people worldwide. There is no cure for dementia at present, but scientists at AviadoBio hope their clinical studies can stop the progression of a particular genetic type of frontotemporal dementia (FTD). 'It may be one of the first dementias to have a definitive treatment, a cure if you like, a really transformative treatment that allows people to live much longer and much more normal lives,' says Prof James Rowe, a consultant neurologist at Cambridge's Addenbrooke's hospital who is involved in the UK trial. FTD mainly affects the front and sides of the brain and, unlike Alzheimer's disease, does not begin with memory loss, which tends to occur later. It is characterised by progressive loss of language and changes in personality and behaviour. Most cases are diagnosed in people aged 45 to 65, but it can affect those in their 20s and 30s. There are an estimated 20,000 to 40,000 people living with FTD in the UK, and between 1 million and 2 million in the world. Rowe says: 'It's a double-edged sword: the young onset, the high genetic burden and rapid illness are also features that perhaps make it more tractable to treat.' The Die Hard and Pulp Fiction actor Bruce Willis, who recently celebrated his 70th birthday, was diagnosed two years ago with FTD, which his family described as a 'cruel disease'. They have not said whether he has a genetic form of FTD. The gene therapy developed by AviadoBio, which was spun out of Prof Christopher Shaw's research lab at King's College London in 2021, targets a type of FTD known as FTD-GRN. This is caused by mutations of a gene that lead to a deficiency of progranulin (GRN), a protein that is essential for maintaining healthy brain cells. AviadoBio, which employs 60 people, signed an exclusive licence agreement with the Japanese pharmaceutical firm Astellas last October to develop the therapy. It is now recruiting patients for its clinical trial in the UK, as well as the US, Poland, Spain, Sweden and the Netherlands. The infusion was administered in Warsaw in March 2024 in one of six patients who have had the treatment so far, in Poland and the US. All patients will be followed for up to five years as part of the trial. AviadoBio expects to publish the first data next year. Three years ago, Jessica Crawford, from Beverley in East Yorkshire, lost her mother, Julia, to FTD, caused by mutations of another gene, C9orf72. In 2014, when Julia was 58, her behaviour changed; the family suspected depression. Previously very sociable, she stopped going out and started playing games such as Candy Crush or watching TV shows 'over and over', her daughter recounts. Her mother initially did not want to see a doctor, and was only diagnosed with FTD in February 2019. By this time she was so confused she once put raw chicken in a sandwich. 'Getting the diagnosis wasn't easy because FTD wasn't well known; my mum was acing in the memory tests,' Jessica says. Julia became increasingly confused and lost the ability to speak, and then to communicate at all. Jessica became her full-time carer in 2020, but her mother deteriorated so much that she had to enter a care home in late 2021, and died the following year. Jessica, 33, found out she also carries the gene mutation, and with her husband decided to conceive through IVF with a pre-implantation genetic diagnosis. When their five embryos were screened, four had the gene mutation, and the fifth resulted in the birth of their son. The couple donated their other four embryos to science and she takes part in GENFI – a long-running UK-led global study of families with FTD across 40 sites. AviadoBio itself was born out of the research done at King's by Shaw, a neurologist who has focused on FTD and amyotrophic lateral sclerosis (ALS) for more than three decades, and Dr Youn Bok Lee and Dr Do Young Lee from the UK Dementia Research Institute's centre based at King's. ALS, the most common form of motor neurone disease, has also been linked to mutations of the GRN gene and leads to muscle weakness, paralysis and eventually death. Shaw acts as the company's chief scientific and clinical adviser, and while the Lees are no longer involved in the firm's research, all three remain shareholders. David Cooper, AviadoBio's chief medical officer, says: 'It was something that hit me when I first joined the company, [when] you look at the MRI scans of patients with a GRN mutation, the frontal and temporal parts of their brain are just melting away … So we really need earlier treatment, an earlier diagnosis and a more organised healthcare approach to deal with it.' AviadoBio's lead product, AVB-101, is infused directly into the brain by a neurosurgeon using a cannula as thin as a strand of angel hair pasta, during a 90-minute procedure guided by MRI. It delivers a functional copy of the progranulin gene to restore appropriate levels of the protein to affected areas of the brain. It is a one-off treatment, and no immunosuppressant drugs are needed afterwards. 'The patients who have FTD are born with almost half of the progranulin levels that you and I might have,' says the chief executive, Lisa Deschamps. 'Our goal in the study is to supplement the GRN gene and restore as much progranulin in these individuals as possible to normal levels to reduce the neurodegeneration effect.' Other medications in development around the world include two gene therapies, from Philadelphia-based Passage Bio and Eli Lilly-owned Prevail Therapeutics, but they do not target the thalamus, the 'relay station' in the brain. Passage Bio's therapies are delivered directly to the cerebrospinal fluid in a single treatment. Denmark's Vesper Bio has developed an oral capsule, designed to act on the GRN gene, that is being trialled at University College London hospital. AviadoBio, whose investors include Johnson & Johnson's innovation arm and the UK not-for-profit LifeArc Ventures, is part of a growing life science cluster in Canary Wharf. At its labs, scientists – assisted by robotics – research how to target a particular gene. 'The UK has real strengths in this area,' says Rowe, pointing to the international GENFI study, run since 2011 by Prof Jonathan Rohrer, a neurologist from UCL Queen Square Institute of Neurology who also sits on AviadoBio's scientific advisory board. 'It's a real win for the UK.'
Yahoo
5 hours ago
- Yahoo
Analysis of the European Hospitals Market 2025-2030: Investment Opportunities for Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Sweden, Belgium, and Ireland
The market is poised for growth, driven by aging demographics, technological advances, and a shift to value-based care. Key opportunities lie in digital health, infrastructure upgrades, and workforce development. Addressing workforce shortages and integrating value-based models will be crucial for sustainability. European Hospital Market Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Europe Hospital Market, By Country, Competition, Forecast and Opportunities, 2020-2030F" has been added to offering. The Europe Hospital Market was valued at USD 0.85 Trillion in 2024, and is expected to reach USD 1.09 Trillion by 2030, rising at a CAGR of 4.35%. This mature and advanced market is anchored by strong public healthcare systems, cutting-edge infrastructure, and a widespread commitment to universal care access. The sector's growth is being fueled by shifting demographics, especially aging populations, along with rapid technological progress and evolving patient expectations. To maintain performance and meet rising demand, hospitals are undergoing digital transformation, expanding service capacity, and focusing on operational modernization. Investments in digital health, workforce development, and facility upgrades are becoming critical. Meanwhile, the shift toward integrated, value-based care models is redefining hospital operations and emphasizing efficiency, outcome measurement, and long-term sustainability, ensuring hospitals remain central to Europe's healthcare landscape. Key Market Driver Aging Population and Chronic Disease Burden Europe's aging population and the resulting increase in chronic diseases are major factors propelling the hospital market. By 2030, the number of Europeans living with Alzheimer's and related dementias is expected to rise to 14 million, escalating the healthcare system's financial and operational demands. The projected economic impact of Alzheimer's care is set to exceed USD 721.37 billion by 2050. As per Eurostat, individuals aged 65 and older made up 21.1% of the EU's population in 2022, and this is forecasted to rise to 32.5% by 2100. Older populations are more prone to conditions such as cardiovascular disease, diabetes, osteoporosis, neurodegenerative disorders, and cancer, all of which increase hospital care needs. Consequently, hospitals are expanding geriatric and chronic care services, modernizing infrastructure, and adapting clinical operations to manage growing patient loads. Key Market Challenge Workforce Shortages and Talent Retention The shortage of skilled medical professionals - including nurses, general practitioners, and specialists - poses a significant challenge for hospitals across Europe. Contributing factors include an aging healthcare workforce, burnout, and early retirements, particularly in under-resourced public systems. Staffing shortages reduce care quality, extend wait times, and hinder hospitals' ability to scale operations or adopt innovative models. The increased use of temporary staffing and overtime also inflates labor costs. Addressing this challenge requires strategic investment in training programs, international recruitment, and adoption of automation technologies such as AI-driven diagnostics and robotic procedures to ease clinical burdens and improve workforce efficiency. Key Market Trend Integration of Value-Based Healthcare Models European hospitals are transitioning from fee-for-service to value-based healthcare (VBHC) models, which emphasize care quality, patient outcomes, and cost-effectiveness. Government mandates and payer incentives are accelerating this shift to improve healthcare delivery and financial sustainability. Hospitals are redesigning care pathways around bundled, patient-centered services with a focus on chronic disease management, preventative care, and post-discharge support. The implementation of performance-based KPIs is reshaping reimbursement models, promoting efficiency, and reducing readmissions. Advanced analytics and predictive tools are increasingly used to track outcomes, manage resources, and demonstrate value - ultimately strengthening hospitals' competitiveness and long-term viability in the evolving European health ecosystem. Key Market Players Profiled: HCA Healthcare UK Fresenius SE & Co. KGaA Spire Healthcare Group plc Orpea Group Asklepios Klinik Barmbek Sana Kliniken AG San Donato Group (Gruppo San Donato) Report Scope In this report, the Europe Hospital Market has been segmented into the following categories: Europe Hospital Market, By Product: Public Private Europe Hospital Market, By Type: General Specialty Multi-Speciality Europe Hospital Market, By Type of Services: In-Patient Services Out-Patient Services Europe Hospital Market, By Bed Capacity: Up to 100 beds 100-500 beds Above 500 beds Europe Hospital Market, By Country: Germany France United Kingdom Italy Spain Netherlands Switzerland Sweden Belgium Ireland Key Attributes Report Attribute Details No. of Pages 125 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $0.85 Trillion Forecasted Market Value (USD) by 2030 $1.09 Trillion Compound Annual Growth Rate 4.3% Regions Covered Europe For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment European Hospital Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data